In summary, the engineered Insulin-MHC-Fc complex represents a tailored immunotherapeutic agent capable of utilizing patients’ endogenous immune cells to achieve antigen-specific clearance of autoreactive T cells in type 1 diabetes. This evidence concerns the gene INS and type 1 diabetes mellitus.